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Betacoronaviruses (betaCoVs) caused the severe acute respiratory syndrome (SARS) 
and Middle East Respiratory Syndrome (MERS) outbreaks, and the SARS-CoV-2 
pandemic1–4. Vaccines that elicit protective immunity against SARS-CoV-2 and 
betaCoVs circulating in animals have the potential to prevent future betaCoV 
pandemics. Here, we show that macaque immunization with a multimeric SARS-CoV-2 
receptor binding domain (RBD) nanoparticle adjuvanted with 3M-052/Alum elicited 
cross-neutralizing antibody (cross-nAb) responses against batCoVs, SARS-CoV-1, 
SARS-CoV-2, and SARS-CoV-2 variants B.1.1.7, P.1, and B.1.351. Nanoparticle 
vaccination resulted in a SARS-CoV-2 reciprocal geometric mean neutralization ID50 
titer of 47,216, and protection against SARS-CoV-2 in macaque upper and lower 
respiratory tracts. Importantly, nucleoside-modified mRNA encoding a stabilized 
transmembrane spike or monomeric RBD also induced SARS-CoV-1 and batCoV 
cross-nAbs, albeit at lower titers. These results demonstrate current mRNA vaccines 
may provide some protection from future zoonotic betaCoV outbreaks, and provide a 
platform for further development of pan-betaCoV vaccines.
SARS coronavirus 1 (SARS-CoV-1), SARS coronavirus 2 (SARS-CoV-2), 
and MERS coronavirus (MERS-CoV) emerged from transmission events 
where humans were infected with bat or camel CoVs5–8. BetaCoVs that 
circulate in civets, bats, and Malayan pangolins are genetically similar 
to SARS-CoV-1 and SARS-CoV-2, and use human ACE2 as a receptor5,6,9–11. 
These SARS-related animal coronaviruses have the potential to be trans-
mitted to humans12. Cross-nAbs capable of neutralizing multiple beta-
CoVs and preventing or treating betaCoV infection have been isolated 
from SARS-CoV-1 infected humans13–24, providing proof-of-concept for 
development of betaCoV vaccines against Sarbecoviruses25.
In mice, vaccine induction of cross-nAbs has been reported for 
CoV pseudoviruses26,27. However, it is unknown whether spike vac-
cination of primates can elicit cross-nAbs against SARS-CoV-1, bat 
betaCoVs, or SARS-CoV-2 escape viruses. A target of cross-nAbs is 
the RBD of spike14,24,25. One such RBD cross-nAb is antibody DH1047, 
which cross-neutralizes SARS-CoV-1, SARS-CoV-2 and bat CoVs15. RBD 
immunogenicity can be augmented by arraying multiple copies on 
nanoparticles, mimicking virus-like particles26–29. Thus, we designed 
a 24-mer SARS-CoV-2 RBD-ferritin nanoparticle vaccine. The RBD nan-
oparticle was constructed by expressing recombinant SARS-CoV-2 
RBD with a C-terminal sortase A donor sequence, and by expressing a 
24-subunit, self-assembling protein nanoparticle Helicobacter pylori 
ferritin with an N-terminal sortase A acceptor sequence30. The RBD 
and ferritin nanoparticle were conjugated together by a sortase A reac-
tion (Fig. 1a, Extended Data Fig. 1)30. Analytical size exclusion chro-
matography and negative stain electron microscopy confirmed that 
RBD was conjugated to the surface of the ferritin nanoparticle (Fig. 1a, 
Extended Data Fig. 1b,c). The RBD sortase A conjugated nanoparti-
cle (RBD-scNP) bound to human ACE2, the receptor for SARS-CoV-2, 
and to potently neutralizing SARS-CoV-2-specific RBD antibodies 
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(Abs) DH1041, DH1042, DH1043, DH1044, and DH104515 (Fig. 1b). The 
cross-nAb DH1047 also bound to the RBD-scNP (Fig. 1b). The RBD-scNP 
lacked binding to SARS-CoV-2 spike Abs that bound outside of the RBD 
(Fig. 1b).
Five cynomolgus macaques were immunized three times intramus-
cularly four weeks apart with 100 μg of RBD-scNP adjuvanted with 
5 μg of the TLR7/8 agonist 3M-052 absorbed to 500 μg of alum (Fig. 1c 
and Extended Data Fig. 1d,e)31. Immunizations were well-tolerated 
in macaques (Extended Data Fig. 2). Immunization with RBD-scNP 
adjuvanted with 3M-052/Alum elicited binding IgG against SARS-CoV-2 
RBD and stabilized Spike ectodomain (S-2P) (Fig. 1d), but immuni-
zation with 3M-052/Alum alone did not (Extended Data Fig. 3a,b). 
Boosting once maximally increased SARS-CoV-2 binding IgG titers 
(Fig. 1d). ACE2 competitive binding assays demonstrated the pres-
ence of ACE2-binding site Abs in the serum of vaccinated macaques 
(Fig. 1e). Similarly, plasma Abs blocked the binding of ACE2-binding 
site-focused, RBD neutralizing antibody DH1041 (Fig. 1e). Vaccine 
induction of nAbs was assessed against a SARS-CoV-2 pseudovirus 
with an aspartic acid to glycine substitution at position 614 (D614G)32. 
Two RBD-scNP immunizations induced potent serum nAbs with fifty 
percent inhibitory reciprocal serum dilution (ID50) neutralization 
titers ranging from 21,292 to 162,603 (Fig. 1f,g). We compared these nAb 
titers to those elicited by cynomolgus macaques immunized twice with 
50 μg of lipid-encapsulated nucleoside-modified mRNA (mRNA-LNP) 
encoding stabilized transmembrane (TM) Spike (S-2P) that is analogous 
to COVID-19 vaccines authorized for emergency use (Extended Data 
Fig. 1f). Serum neutralization titers against SARS-CoV-2 D614G pseu-
dovirus elicited by RBD-scNP immunization were significantly higher 
than titers elicited by two S-2P mRNA-LNP immunizations (Fig. 1i, group 
geometric mean ID50 47,216 versus 6,469, P = 0.0079 Exact Wilcoxon 
test, n=5)33,34. When compared to natural human infection, RBD-scNP 
vaccination elicited higher ID50 neutralization titers (Fig. 1j). Thus, 
RBD-scNP adjuvanted with 3M-052/Alum elicits significantly higher 
neutralizing titers in macaques compared to current vaccine platforms 
or natural human infection.
The SARS-CoV-2 variant B.1.1.7 or United Kingdom variant is spread-
ing globally, and has been suggested to have higher infectivity than 
the Wuhan-1 strain35,36. B.1.351 lineage viruses are widespread in the 
Republic of South Africa36–38, and along with Brazilian variant P.1 are 
of concern due to their neutralization-resistant phenotype mediated 
by mutations in the RBD at K417N, E484K, and N501Y39. Each of these 
mutations were distal to the cross-nAb DH1047 binding site owing to 
its long HCDR3 used to contact RBD; however, the E484K mutation was 
within the binding site of RBD nAb DH1041 (Fig. 2a,b)15. Thus, DH1041 
binding to SARS-CoV-2 RBD was knocked out by the E484K mutation, 
but DH1047 binding to RBD was unaffected by K417N, E484K, or N501Y 
(Fig. 2c,d and Extended Data Fig. 3).
We determined whether RBD-scNP or mRNA-LNP immunization 
elicited nAbs against these particular SARS-CoV-2 variants. RBD-scNP 
macaque serum potently neutralized a pseudovirus bearing the 
D614G spike and the B.1.1.7 spike (Fig. 2d,e). Similarly, S-2P mRNA-LNP 
immunization elicited equivalent titers of nAbs against the B.1.1.7 
and D614G variants of SARS-CoV-2, although titers were lower than 
RBD-scNP immunization (Fig. 2d,e). Macaque serum from RBD-scNP 
or mRNA-LNP immunization neutralized SARS-CoV-2 WA-1, B.1.351, and 
P.1 pseudoviruses, with ID80 titers being more potent for the RBD-scNP 
group (Fig. 2f-i). On average, the RBD-scNP group neutralization titers 
decreased by 3-fold against B.1.351 or P.1, whereas the mRNA-LNP group 
decreased by 6-fold for B.1.351 and 10-fold for P.1 based on ID50 titers 
(Fig. 2g,i). Additionally, we observed RBD-scNP and S-2P mRNA-LNP 
immune plasma IgG binding to SARS-CoV-2 S was unaffected by muta-
tions observed in Danish minks, B.1.351, P.1, and B.1.1.7 SARS-CoV-2 
strains36,37,40 (Extended Data Fig. 3). In summary, both vaccines tested 
here elicited nAbs that were unaffected by the mutations in the B.1.1.7 
strain. However, nAbs elicited by RBD-scNP more potently neutralized 
the difficult-to-neutralize B.1.351 and P.1 virus strains than nAbs elicited 
with S-2P mRNA-LNP immunization.
SARS-related CoVs that circulate in humans and animals remain a 
threat for future outbreaks12,41,42. Therefore, we examined neutrali-
zation of SARS-CoV-1 and SARS-related group 2b batCoV-WIV-1 and 
SARS-related batCoV-SHC014 viruses by immune sera from macaques 
vaccinated with the RBD-scNP, mRNA-LNP encoding monomeric 
RBD or S-2P (Extended Data Fig. 1e-g)6,9,41,42. After two immunizations, 
RBD-scNP, S-2P mRNA-LNP, and the RBD monomer mRNA-LNP elic-
ited nAbs against SARS-CoV-1, batCoV-WIV-1, and batCoV-SHC014 
(Fig. 3a, Extended Data Fig. 4). Neutralization was more potent for 
replication-competent SARS-CoV-2 virus compared to the other 
three SARS-related viruses (Fig. 3a, Extended Data Fig. 4), with neu-
tralization titers varying up to 4-fold within the RBD-scNP group 
(Extended Data Fig. 4). Overall, RBD-scNP immunization elicited the 
highest neutralization titers (Fig. 3a, Extended Data Fig. 4). Small 
increases in neutralization potency were gained by boosting a third 
time with the RBD-scNP (Fig. 3b). Moreover, RBD-scNP immunization 
elicited cross-reactive plasma IgG against SARS-CoV-2, SARS-CoV-1, 
batCoV-RaTG13, batCoV-SHC014, pangolin CoV-GXP4L Spike proteins 
(Fig. 3c and Extended Data Fig. 5a,c). Binding antibody titers were high 
for these spikes, even in instances where neutralization titers were low 
suggesting non-nAbs contributed to binding titers. RBD-scNP immune 
plasma IgG did not bind spike from the four endemic human CoVs or 
MERS-CoV (Extended Data Fig. 5a,c). The lack of binding by plasma IgG 
to these latter five S ectodomains was consistent with RBD sequence 
divergence among groups 1, 2a, 2b and 2c coronaviruses (Fig. 3f and 
Extended Data Fig. 6-7). The SARS-CoV-2 spike induced cross-nAbs 
against multiple group 2b SARS-related betaCoVs, with the highest 
titers induced by RBD-scNP.
Immune sera from RBD-scNP-immunized macaques exhibited a 
similar cross-neutralizing profile as the cross-nAb DH1047. DH1047 
bound with <0.02 nM affinity to monomeric SARS-CoV-2 RBD (Extended 
Data Fig. 5b), and bound the RBD-scNP (Fig. 1b). The cross-reactive 
DH1047 epitope is adjacent to the N-terminus of the ACE2-binding 
site, distinguishing it from dominant ACE2 binding site-focused nAbs 
such as DH1041 (Fig. 3d)15, and it has high group 2b sequence conserva-
tion (Fig. 3e). Overall RBD sequences within betaCoV groups are more 
conserved than sequences from different groups (Fig. 3f and Extended 
Data Fig. 6-7). The presence of DH1047-like antibodies was determined 
with DH1047 blocking assays. Plasma from all RBD-scNP-immunized 
macaques blocked the binding of ACE2 and DH1047 to SARS-CoV-2 S-2P 
ectodomain (Fig. 3g and Extended Data Fig. 5d). The DH1047-blocking 
antibodies were cross-reactive as they also potently blocked DH1047 
binding to batCoV-SHC014 S-2P (Fig. 3g). RBD-scNP immunization elic-
ited higher magnitudes of DH1047 blocking Abs than S-2P mRNA-LNP 
immunization of macaques, Pfizer/BNT162b2 mRNA-LNP immuniza-
tion of humans, or SARS-CoV-2 human infection (Fig. 3h and Extended 
Data Fig. 5d). ACE2 blocking was high in all groups (Fig. 3h). While 5 of 
5 RBD-scNP-vaccinated macaques exhibited potent DH1047 serum 
blocking activity, 3 of 4 immunized humans and 9 of 22 of COVID-19 
convalescent humans had detectable serum DH1047 blocking activity 
(Fig. 3h). Thus, the DH1047-like antibody response was subdominant 
in infected or immunized humans and S-2P mRNA-LNP-immunized 
macaques, but was a dominant antibody response to RBD-scNP vac-
cination.
To determine vaccine protection against coronavirus infection, 
we challenged RBD-scNP-vaccinated and S-2P mRNA-LNP primed/
RBD-scNP boosted monkeys with 105 plaque forming units of 
SARS-CoV-2 virus via intratracheal and intranasal routes after their 
last boost (Fig. 4a). NAbs were detectable in all macaques 2 weeks 
after the final immunization (Fig. 3b and Extended Data Fig. 4b,c). 
Bronchoalveolar lavage (BAL) fluid was collected 2 days post chal-
lenge (Fig. 4a). Infectious SARS-CoV-2 was detectable in BAL fluid from 
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S-2P mRNA-LNP/RBD-scNP-immunized macaques (Fig. 4b). Copies 
of Envelope (E) and Nucleocapsid (N) subgenomic RNA in fluid from 
nasal swabs and bronchoalveolar lavage (BAL) two and four days after 
challenge was used to quantify SARS-CoV-2 replication (Fig. 4a). On day 
2 after challenge, unimmunized macaques had an average of 1.3x105 
and 1.2x104 copies/mL of E sgRNA in the nasal swab and BAL fluids, 
respectively (Fig. 4c,d). In contrast, RBD-scNP-vaccinated monkeys 
and 4 of 5 S-2P mRNA-LNP monkeys had undetectable levels of E sgRNA 
in the upper and lower respiratory tract (Fig. 4c,d). We sampled mon-
keys again 2 days later, and found no detectable E sgRNA in any vac-
cinated monkey BAL or nasal swab samples (Fig. 4b,c). Similarly, all 
RBD-scNP-vaccinated macaque had undetectable N sgRNA in BAL and 
the nasal swab fluid, except one macaque that had 234 copies/mL of N 
sgRNA detected on day 2 in nasal swab fluid (Fig. 4e,f). Virus replication 
was undetectable in this macaque by the fourth day after challenge 
(Fig. 4e). Additionally, all but one mRNA-LNP/RBD-scNP-immunized 
macaque had undetectable N sgRNA in BAL or nasal swab samples 
(Fig. 4e,f). Moreover, SARS-CoV-2 nucleocapsid antigen was undetect-
able in the lung tissue of all vaccinated macaques, but was detected in 
all control macaques (Fig. 4g and Extended Data Fig. 8). Hematoxylin 
and eosin staining of lung tissue showed a reduction in inflammation 
in immunized macaques compared to control macaques (Extended 
Data Fig. 8 and Extended Data Table 1).
Finally, mucosal immunity to SARS-CoV-2 were examined when 
possible both before and after SARS-CoV-2 challenge (Extended Data 
Fig. 9). IgG from concentrated BAL bound to spike and blocked ACE-2, 
DH1041, and DH1047 binding to spike (Extended Data Fig. 9b-d). Each 
response was higher in the BAL from monkeys immunized three times 
with RBD-scNP compared to monkeys immunized two times with S-2P 
mRNA-LNP and boosted once with RBD-scNP, although the BAL was 
collected from each group at different timepoints. Unconcentrated 
nasal wash samples from monkeys immunized with either RBD-scNPs 
or S-2P mRNA-LNP prime/RBD-scNP boost showed similar low levels of 
spike-binding IgG post challenge (Extended Data Fig. 9e). Nonetheless, 
RBD-scNP-immunization elicited RBD-specific mucosal antibodies.
As three coronavirus epidemics have occurred in the past 20 years, 
there is a need to develop effective pancoronavirus vaccines prior to the 
next pandemic25. The epitopes of betaCoV cross-nAbs, such as DH1047, 
provide clear targets for vaccines aiming to protect against multiple 
CoVs13–15,43. We have shown that immunization with RBD-scNP adju-
vanted with a toll-like receptor agonist 3M-052, and spike mRNA-LNP 
to a lesser extent, induces cross-nAbs against multiple SARS-related 
human and bat betaCoVs in primates. These results demonstrate that 
SARS-CoV-2 vaccination with either the RBD-scNP or spike mRNA-LNP 
vaccines similar to those authorized for use in humans, will likely elicit 
cross-nAbs with the potential to prevent future group 2b betaCoV spillo-
ver from bats to humans12,26.
The emergence of SARS-CoV-2 neutralization-resistant and highly 
infectious variants continues to be a concern for vaccine efficacy. 
RBD-scNP and SARS-CoV-2 spike mRNA-LNP immunizations elicited 
SARS-CoV-2 nAbs against SARS-CoV-2 D614G, B.1.1.7, P.1, and B.1.351 
strains. The nAbs elicited by RBD-scNP and S-2P mRNA-LNP were of 
different specificities since RBD-scNP-induced nAbs showed a smaller 
reduction in neutralization potency across the different variants 
compared to S-2P mRNA-LNP immune sera. Our results are consistent 
with the demonstration that current COVID-19 vaccines have reduced 
efficacy against the B.1.351 SARS-CoV-2 variant44–49.
The RBD-scNP vaccine is a promising platform for pancoronavi-
rus vaccine development for the following reasons. The RBD-scNP 
vaccine induced apparent sterilizing immunity in the upper respira-
tory tract, which has not been routinely achieved with SARS-CoV-2 
vaccination in macaques50,51. Additionally, the extraordinarily high 
neutralization titers achieved by RBD-scNP vaccination bode well for 
an extended duration of protection. Despite the induction of high levels 
of antibody we observed no evidence of increased immunopathology, 
inflammatory cytokines or virus replication indicative vaccine-elicited 
antibody-dependent enhancement. Lack of in vivo infection enhance-
ment is consistent with studies using SARS-CoV-2 monoclonal Abs15. 
3M-052 adsorbed to Alum is in clinical testing (NCT04177355) gen-
erating a potential translational pathway for RBD-scNP adjuvanted 
with 3M-052. The RBD-scNP/3M-052 vaccine represents a platform 
for producing pancoronavirus vaccines that could prevent, rapidly 
temper, or extinguish the next spillover of a coronavirus into humans.
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Fig. 1 | SARS-CoV-2 receptor binding domain (RBD) sortase-conjugated 
nanoparticles (scNPs) elicits extremely high titers of SARS-CoV-2 pseudovirus 
neutralizing antibodies (nAbs). a SARS-CoV-2 RBD (blue and red) Helicobacter 
pylori ferritin (gray) nanoparticle sortase conjugation. A model and 
two-dimensional class average of negative stain electron microscopy of the 
resultant RBD nanoparticle are shown. b Biolayer interferometry SARS-CoV-2 
antibody and ACE2 receptor binding to RBD nanoparticles. N-terminal  
domain (NTD), infection enhancing non-neutralizing antibody (nonAbs IE), 
non-neutralizing antibody (nonAb). Symbols represent values from 3 independent 
experiments and bars represent the mean and standard error of the mean (s.e.m.).  
c Cynomolgus macaque immunogenicity and challenge study design. d Macaque 
serum IgG binding titer as area-under-the curve of the log10-transformed curve (log 
AUC) to recombinant SARS-CoV-2 stabilized Spike ectodomain (S-2P), RBD, NTD, 
and Fusion peptide (FP). Group mean±s.e.m. are shown in d and e (n = 5 macaques). 
e Plasma antibody blocking of SARS-CoV-2 S-2P binding to ACE2-Fc and RBD 
neutralizing antibody DH1041. f,g f Dose-dependent serum neutralization of 
SARS-CoV-2 D614G pseudovirus infection of ACE2-expressing 293T cells and g 
neutralization ID50 and ID80 titers. Serum was examined after two immunizations. 
The mean value of duplicates is shown in f. h SARS-CoV-2 D614G pseudovirus serum 
neutralization titer over time for individual macaques. i Serum neutralization ID50 
titers from macaques immunized twice with protein RBD nanoparticles (blue) or 
nucleoside-modified mRNA-LNP expressing S-2P (burgundy) (**P = 0.0079, 
Two-tailed Exact Wilcoxon test, n = 5 macaques). j Serum neutralization titers for 
macaques immunized twice with RBD-scNP (blue, n =5 macaques) or humans with 
asymptomatic infection (n=34 individuals), symptomatic infection (n=71 
individuals), or hospitalized (n=60 individuals) (**P<0.01, Two-tailed Wilcoxon 
test). Horizontal bars are the group geometric mean in i and j. Pre-vaccination 
serum or nAb spiked serum were used as controls in f, g, and h.



























Fig 2 | RBD-scNP immunization elicits higher titers of nAbs against more 
transmissible or neutralization-resistant SARS-CoV-2 variants than 
stabilized spike mRNA-LNP vaccination. a,b The location of K417, E484, and 
N501 (spheres) present in the B.1.351 variant are shown in the cryo-EM 
structures of RBD nAbs a DH1041 (red) and b DH1047 (magenta) bound to the 
RBD (gray) of S trimers (PDB: 7LAA and 7LD1)15. c ACE2 receptor, DH1041, and 
DH1047 ELISA binding titer as log AUC for wildtype and mutant SARS-CoV-2 
Spike RBD monomers. d Serum neutralization ID50 (left) and ID80 titers for 
SARS-CoV-2 D614G and SARS-CoV-2 B.1.1.7 pseudoviruses from immunized 
macaques. Symbols represent individual macaques and horizontal bars are 
group means (**P = 0.0079, Two-tailed Exact Wilcoxon test, n = 5 macaques).  
e Fold decrease in neutralization potency between neutralization of 
SARS-CoV-2 D614G and SARS-CoV-2 B.1.1.7 pseudoviruses. Fold change is 
shown for RBD-scNP-immunized and mRNA-LNP-immunized macaques based 
ID50 (left) and ID80 (right) titers. Horizontal bars are the group mean.  
f Vaccinated macaque serum neutralization ID50 (left) and ID80 titers (right) 
against WA-1 and B.1.351 pseudovirus. Symbols and horizontal bars are shown 
the same as in d (*P = 0.0159 and **P = 0.0079, Two-tailed Exact Wilcoxon test, n 
= 5 macaques). g Fold decrease in neutralization potency between 
neutralization of SARS-CoV-2 WA-1 and B.1.351 pseudoviruses. Fold change is 
shown the same as in e. h Vaccine-induced neutralization of SARS-CoV-2 WA-1 
and P.1 pseudovirus infection of ACE2 and TMPRSS2-expressing 293 cells. 
Symbols and horizontal bars are shown the same as in d (*P = 0.0159 and  
**P = 0.0079, Two-tailed Exact Wilcoxon test, n = 5 macaques). i Fold decrease in 
neutralization potency as shown in e between neutralization of SARS-CoV-2 
WA-1 and P.1 pseudoviruses.




























Fig. 3 | RBD-scNP vaccine induction of serum cross-neutralization of 
SARS-related betacoronavirus infection. a Serum neutralization ID50 titers 
from macaques immunized twice with RBD-scNP, S-2P mRNA-LNP, or RBD 
mRNA-LNP for SARS-CoV-1 and SARS-CoV-2 and SARS-related batCoVs (WIV-1 
and SHC014). Symbols indicate individual macaques and black bars show the 
group geometric mean (Two-tailed Exact Wilcoxon test, n = 5 or 8 macaques).  
b Serum cross-neutralization ID50 titers before (gray), after two (light blue) or 
after three (blue) RBD-scNP immunizations. Bars represent the group 
geometric mean. c Human, bat, and pangolin SARS-related betaCoV S protein 
ELISA log AUC titer for plasma IgG from macaques immunized twice with 
RBD-scNP. ECD, ectodomain. d Structural comparison of the epitopes of 
SARS-CoV-2-specific neutralizing RBD antibody (DH1041, red, PDB ID: 7LAA) 
and cross-neutralizing RBD antibody (DH1047, magenta, PDB ID: 7LD1). (Left) 
Cartoon view of Spike (green), RBD (gray), Receptor Binding Motif (RBM, blue). 
(Right) Overlay of the RBDs of the two complexes from their respective 
cryo-EM structures. e RBD colored by conservation within group 2b 
betacoronaviruses. DH1047 epitope is shown in magenta outline. f Heatmaps 
displaying pairwise amino acid sequence similarity for 57 representative 
betaCoVs. g, h Plasma/serum antibody blocking of S-2P binding to ACE2 (gray) 
and DH1047 (navy blue). g Kinetics of SARS-CoV-2 or batCoV-SHC014 blocking 
by serum from macaques immunized twice with RBD-scNP. Group mean±s.e.m. 
are shown (n = 5 macaques). h Blocking activity by serum from macaques 
immunized twice with RBD-scNP or S-2P mRNA-LNP and humans immunized 
twice with Pfizer BNT162b2 or naturally infected with SARS-CoV-2. Each symbol 
represents an individual subject and filled bars indicate the group mean in h. 
Positivity threshold (dashed line) is greater than 20% in g and h.



























Fig. 4 | RBD-scNP vaccination alone or as a boost completely prevents virus 
replication in the upper and lower respiratory tract after intranasal and 
intratracheal SARS-CoV-2 challenge in nearly all macaques. a. Macaque 
intranasal/intratracheal SARS-CoV-2 challenge study design. Blue and maroon 
arrows indicate the time points for RBD-scNP and mRNA-LNP immunizations 
respectively. b Infectious virus in macaque BAL fluid two days after challenge. 
c-f. Quantification of viral envelope (E) gene or nucleocapsid (N) gene 
subgenomic RNA (sgRNA) in unimmunized (gray) and RBD-scNP-immunized 
(blue), and S-2P mRNA-LNP prime/RBD-scNP boosted (burgundy) macaques. 
sgRNA in nasal swabs and bronchoalveolar lavage (BAL) was quantified two 
(left) and four (right) days after challenge. Limit of detection (LOD) for the 
assay is 150 copies/mL. Symbols and bars are shown as in b. g Nucleocapsid 
immunohistochemistry of lung tissue sections seven days post challenge. 
(Left) A representative image from 1 macaque from each group of 5 macaques is 
shown. Red arrows indicate site of antigen positivity. All images are shown at 
10X magnification with 100 micron scale bars. (Right) Quantification of 
antigen positivity. In each panel symbols represent individual macaques with 
the group mean shown as a black horizontal bar.





























Animals, immunizations, and human samples
Rhesus and cynomolgus macaques were housed and treated in 
AAALAC-accredited institutions. The study protocol and all veteri-
narian procedures were approved by the Bioqual IACUC per a memo-
randum of understanding with the Duke IACUC, and were performed 
based on standard operating procedures. Nucleoside-modified mes-
senger RNA encapsulated in lipid nanoparticles (mRNA-LNP) was 
prepared as previously stated52,53. Rhesus macaques (n=8 macaques) 
were immunized intramuscularly with 50μg of mRNA-LNP encod-
ing the receptor binding domain (RBD) monomer. Cynomolgus 
macaques (n=5 macaques) were immunized twice with 50μg of 
mRNA-LNP encoding the transmembrane Spike protein stabilized 
with K986P and V987P mutations and boosted once with 100 μg 
of RBD-scNP adjuvanted with 5 μg of 3M-052 aqueous formulation 
(AF) admixed with 500 μg of Alum in PBS. An additional group of 
cynomolgus macaques (n=5 macaques) were immunized in the right 
and left quadriceps with 100 μg of RBD-scNP adjuvanted with 5 μg of 
3M-052 aqueous formulation (AF) admixed with 500 μg of Alum in 
PBS31. The mixture for immunization consisted of 250 μL of RBD-scNP 
mixed with 250 μL of 0.02 mg/ml 3M-052, 2 mg/ml Alum. Group sizes 
were selected such that statistical significance could be reached with 
between group nonparametric statistical comparisons. Macaques 
were on average 8 or 9 years old and ranged from 2.75 to 8 kg in body 
weight. Male and females per group were balanced when macaque 
availability permitted it. Studies were performed unblinded. Animals 
were evaluated by Bioqual veterinary staff before during and after 
immunizations. In the animals studied, CBCs and chemistries were 
obtained throughout the immunization regimen and no significant 
abnormalities were noted. Of the 10 cynomolgus macaques, there 
were no adverse events reported at injection sites. Over the course 
of the study, 2 cynomolgus macaques experienced slight weight 
loss. Two cynomolgus macaques showed a single incidence of poor 
appetite, with one additional cynomolgus macaque showing poor 
appetite intermittently throughout the study. Additionally, one 
macaque presented with an infected lymph node biopsy site that 
responded to appropriate veterinary treatment. Biospecimens before 
challenge, 2 days post-challenge, and 4 days post challenge were col-
lected as described previously15. Human samples were obtained with 
informed consent. All recruitment, sample collection, and experi-
mental procedures using human samples have been approved by the 
Duke Institutional Review Board.
SARS-CoV-2 intranasal and intratracheal challenge
All animals were challenged at week 11 (3 weeks after last vaccina-
tion) through combined intratracheal (IT, 3.0 mL) and intranasal (IN, 
0.5 mL per nostril) inoculation with an infectious dose of 105 PFU of 
SARS-CoV-2 (2019-nCoV/USA-WA1/2020). The stock was generated at 
BIOQUAL (lot# 030120-1030, 3.31 x 105 PFU/mL) from a p4 seed stock 
obtained from BEI Resources (NR-52281). The stock underwent deep 
sequencing to confirm homology with the WA1/2020 isolate. Virus was 
stored at -80 °C prior to use, thawed by hand and placed immediately 
on wet ice. Stock was diluted to 2.5x104 PFU/mL in PBS and vortexed 
gently for 5 seconds prior to inoculation. Nasal swabs, bronchoalveolar 
lavage (BAL), plasma, and serum samples were collected seven days 
before, two days after, and four days after challenge. Unimmunized 
control cynomolgus macaques (N=5) comprised were macaques that 
had been infused with a 10 mg/kg of a control antibody (CH65) and 
then 3 days later challenged with the same challenge dose and stock 
of SARS-CoV-2 as used in RBD-scNP-immunized macaques or 2P spike 
protein mRNA-LNP/RBD-scNP-immunized macaques. Protection 
from SARS-CoV-2 infection was determined by quantitative PCR of 
SARS-CoV-2 subgenomic Envelope (E) and the more sensitive Nucle-
ocapsid (N) RNA (E or N sgRNA)39 as stated below.
SARS-CoV-2 protein production
The CoV ectodomain constructs were produced and purified as 
described previously54. The Spike (S) ectodomain was stabilized by 
the introduction of 2 prolines at amino acid positions 986 and 987 and 
referred to as S-2P. Plasmids encoding Spike-2P and HexaPro55 were 
transiently transfected in FreeStyle 293 cells (Thermo Fisher) using 
Turbo293 (SpeedBiosystems) or 293Fectin (ThermoFisher). All cells 
were tested monthly for mycoplasma. The constructs contained an HRV 
3C-cleavable C-terminal twinStrepTagII-8xHis tag. On day 6, cell-free 
culture supernatant was generated by centrifugation of the culture and 
filtering through a 0.8 um filter. Protein was purified from filtered cell 
culture supernatants by StrepTactin resin (IBA) and by size exclusion 
chromatography using Superose 6 column (GE Healthcare) in 10 mM 
Tris pH8,150 mM NaCl or 2 mM Tris pH 8, 200 mM NaCl, 0.02% NaN3. 
ACE-2-Fc was expressed by transient transfection of Freestyle 293-F 
cells54. ACE2-Fc was purified from cell culture supernatant by HiTrap 
protein A column chromatography and Superdex200 size exclusion 
chromatography in 10 mM Tris pH8,150 mM NaCl. SARS-CoV-2 NTD 
was produced as previously described56. SARS-CoV-2 fusion peptide 
was synthesized (GenScript).
Sortase A conjugation of SARS-CoV-2 RBD to H. pylori ferritin 
nanoparticles
Wuhan strain SARS-CoV-2 RBD was expressed with sortase A donor 
sequence LPETGG encoded at its c-terminus. C-terminal to the sortase 
A donor sequence was an HRV-3C cleavage site, 8X his tag, and a twin 
StrepTagII (IBA). The SARS-CoV-2 RBD was expressed in Freestyle293 
cells and purified by StrepTactin affinity chromatography (IBA) and 
superdex200 size exclusion chromatography as stated above. H. pylori 
ferritin particles were expressed with a pentaglycine sortase A accep-
tor sequence encoded at its N-terminus of each subunit. For affinity 
purification of ferritin particles, 6XHis tags were appended C-terminal 
to a HRV3C cleavage site. Ferritin particles with a sortase A N-terminal 
tag were buffer exchanged into 50mM Tris, 150mM NaCI, 5mM CaCI2, 
pH7.5. 180 μM SARS-CoV-2 RBD was mixed with 120 μM of ferritin 
subunits and incubated with 100 μM of sortase A overnight at room 
temperature. Following incubation conjugated particles were isolated 
from free ferritin or free RBD by size exclusion chromatography using 
a Superose6 16/60 column.
Biolayer interferometry binding assays
Binding was measured using an OctetRed 96 (ForteBio). Anti-human IgG 
capture (AHC) sensor tips (Forte Bio) were hydrated for at least 10 min-
utes in PBS. ACE2 and monoclonal Abs were diluted to 20 μg/mL in PBS 
and placed in black 96-well assay plate. The influenza antibody CH65 
was used as the background reference antibody. The RBD nanoparticle 
was diluted to 50 μg/mL in PBS and added to the assay plate. Sensor 
tips were loaded with antibody for 120 s. Subsequently, the sensor tips 
were washed for 60 s in PBS to removed unbound antibody. The sensor 
tips were incubated in a fresh well of PBS to establish baseline reading 
before being dipped into RBD-scNP to allow association for 400 s. 
To measure dissociation of the antibody-RBD-scNP complex, the tip 
was incubated in PBS for 600 s. At the end of dissociation, the tip was 
ejected and a new tip was attached to load another antibody. The data 
was analyzed with Data Analysis HT v12 (ForteBio). Background binding 
observed with CH65 was subtracted from all values. All binding curves 
were aligned to the start of association. The binding response at the 
end of the 400 s association phase was plotted in GraphPad Prism v9.0.
Surface plasmon resonance (SPR) assays
SPR measurements of DH1047 antigen binding fragment (Fab) binding 
to monomeric SARS-CoV-2 RBD proteins were performed in HBS-EP+ 
running buffer using a Biacore S200 instrument (Cytiva). Assays were 



























via its twin-StrepTagII onto a Series S Streptavidin chip to a level of 
300-400 resonance units (RU). The antibody Fabs were injected at 
0.5 to 500 nM over the captured S proteins using the single cycle kinet-
ics injection mode at a flow rate of 50 μL/min. Fab association occurred 
for 180 s followed by a dissociation of 360 seconds after the end of the 
association phase. At the end of the dissociation phase the RBD was 
regenerated with a 30 s injection of glycine pH1.5. Binding values were 
analyzed with Biacore S200 Evaluation software (Cytiva). References 
included blank streptavidin surface along with blank buffer binding 
and was subtracted from DH1047 values to account for signal drift 
and non-specific protein binding. A 1:1 Langmuir model with a local 
Rmax was used for curve fitting. Binding rates and constants were 
derived from the curve. Representative results from two independent 
experiments are shown.
BAL plaque assay
SARS-CoV-2 Plaque assays were performed in the Duke Regional Bio-
containment BSL3 Laboratory (Durham, NC) as previously described57. 
Serial dilutions of BAL fluid-were incubated with Vero E6 cells 
in a standard plaque assay58,59. BAL and cells were incubated at 37 °C, 
5% CO2 for 1 hour. At the end of the incubation, 1 mL of a viscous 
overlay (1:1 2X DMEM and 1.2% methylcellulose) was added to each well. 
Plates are incubated for 4 days. After fixation, staining and washing, 
plates were dried and plaques from each dilution of BAL sample were 
counted. Data are reported as plaque forming units per milliliter of 
BAL fluid. Samples were collected in virus transport media from six 
unimmunized, SARS-CoV-2-challenged macaques for comparison to 
vaccinated macaques.
SARS-CoV-2 pseudovirus neutralization
For SARS-CoV-2 D614G and SARS-CoV-2 B.1.1.7 pseudovirus neutrali-
zation assays, neutralization of SARS-CoV-2 Spike-pseudotyped virus 
was performed by adapting an infection assay described previously 
with lentiviral vectors and infection in 293T/ACE2.MF (the cell line 
was kindly provided by Drs. Mike Farzan and Huihui Mu at Scripps). 
Cells were maintained in DMEM containing 10% FBS and 50 μg/ml 
gentamicin. An expression plasmid encoding codon-optimized 
full-length spike of the Wuhan-1 strain (VRC7480), was provided by 
Drs. Barney Graham and Kizzmekia Corbett at the Vaccine Research 
Center, National Institutes of Health (USA). The D614G mutation was 
introduced into VRC7480 by site-directed mutagenesis using the 
QuikChange Lightning Site-Directed Mutagenesis Kit from Agilent 
Technologies (Catalog # 210518). The mutation was confirmed by 
full-length spike gene sequencing. Pseudovirions were produced in 
HEK 293T/17 cells (ATCC cat. no. CRL-11268) by transfection using 
Fugene 6 (Promega, Catalog #E2692). Pseudovirions for 293T/ACE2 
infection were produced by co-transfection with a lentiviral backbone 
(pCMV ΔR8.2) and firefly luciferase reporter gene (pHR’ CMV Luc)60. 
Culture supernatants from transfections were clarified of cells by 
low-speed centrifugation and filtration (0.45 μm filter) and stored in 
1 ml aliquots at -80 °C.
For 293T/ACE2 neutralization assays, a pre-titrated dose of virus 
was incubated with 8 serial 3-fold or 5-fold dilutions of mAbs in dupli-
cate in a total volume of 150 μL for 1 h at 37 °C in 96-well flat-bottom 
poly-L-lysine-coated culture plates (Corning Biocoat). SARS-CoV-2 RBD 
nAb DH1043 spiked into normal human serum was used as a positive 
control. Cells were suspended using TrypLE express enzyme solution 
(Thermo Fisher Scientific) and immediately added to all wells (10,000 
cells in 100 μL of growth medium per well). One set of 8 control wells 
received cells + virus (virus control) and another set of 8 wells received 
cells only (background control). After 66-72 h of incubation, medium 
was removed by gentle aspiration and 30 μL of Promega 1x lysis buffer 
was added to all wells. After a 10-minute incubation at room tempera-
ture, 100 μl of Bright-Glo luciferase reagent was added to all wells. After 
1-2 minutes, 110 μl of the cell lysate was transferred to a black/white plate 
(Perkin-Elmer). Luminescence was measured using a PerkinElmer Life 
Sciences, Model Victor2 luminometer.
To make WA-1, P.1, and B.1.351 SARS-CoV-2 pseudoviruses, human 
codon-optimized cDNA encoding SARS-CoV-2 S glycoproteins of vari-
ous strains were synthesized by GenScript and cloned into eukaryotic 
cell expression vector pcDNA 3.1 between the BamHI and XhoI sites. 
Pseudovirions were produced by co-transfection of Lenti‐X 293T 
cells with psPAX2(gag/pol), pTrip-luc lentiviral vector and pcDNA 3.1 
SARS-CoV-2-spike-deltaC19, using Lipofectamine 3000. The super-
natants were harvested at 48h post transfection and filtered through 
0.45-μm membranes and titrated using 293-ACE2-TMPRSS2 cells 
(HEK293T cells that express ACE2 protein).
For the neutralization assay, 50 μL of SARS-CoV-2 S pseudovirions 
were pre-incubated with an equal volume of medium containing serum 
at varying dilutions at room temperature for 1 h, then virus-antibody 
mixtures were added to 293T-ACE2 (WA-1 and B.1.351 assays) or 
293-ACE2-TMPRSS2 (WA-1 and P.1 assays) cells in a 96-well plate. After 
a 3 h incubation, the inoculum was replaced with fresh medium. Cells 
were lysed 24 h later, and luciferase activity was measured using lucif-
erin. Controls included cell only control, virus without any antibody 
control and positive control sera. Neutralization titers are the serum 
dilution (ID50/ID80) at which relative luminescence units (RLU) were 
reduced by 50% and 80% compared to virus control wells after subtrac-
tion of background RLUs.
Live virus neutralization assays
Full-length SARS-CoV-2, SARS-CoV, WIV-1, and RsSHC014 viruses were 
designed to express nanoluciferase (nLuc) and were recovered via 
reverse genetics as described previously61–63. Virus titers were measured 
in Vero E6 USAMRIID cells, as defined by plaque forming units (PFU) per 
ml, in a 6-well plate format in quadruplicate biological replicates for 
accuracy. For the 96-well neutralization assay, Vero E6 USAMRID cells 
were plated at 20,000 cells per well the day prior in clear bottom black 
walled plates. Cells were inspected to ensure confluency on the day of 
assay. Serum samples were tested at a starting dilution of 1:20 and were 
serially diluted 3-fold up to nine dilution spots. Serially diluted serum 
samples were mixed in equal volume with diluted virus. Antibody-virus 
and virus only mixtures were then incubated at 37oC with 5% CO2 for 
one hour. Following incubation, serially diluted sera and virus only 
controls were added in duplicate to the cells at 75 PFU at 37oC with 
5% CO2. After 24 hours, cells were lysed, and luciferase activity was 
measured via Nano-Glo Luciferase Assay System (Promega) according 
to the manufacturer specifications. Luminescence was measured by a 
Spectramax M3 plate reader (Molecular Devices, San Jose, CA). Virus 
neutralization titers were defined as the sample dilution at which a 
50% reduction in RLU was observed relative to the average of the virus 
control wells. Prebleed or unimmunized control macaque values were 
subtracted from WIV-1 neutralization titers, but all other viruses were 
not background subtracted.
Biocontainment and biosafety
All work described here was performed with approved standard oper-
ating procedures for SARS-CoV-2 in a biosafety level 3 (BSL-3) facility 
conforming to requirements recommended in the Microbiological 
and Biomedical Laboratories, by the U.S. Department of Health and 
Human Service, the U.S. Public Health Service, and the U.S. Center for 
Disease Control and Prevention (CDC), and the National Institutes of 
Health (NIH).
Plasma and mucosal IgG blocking of ACE2 binding
For ACE2 blocking assays, plates were coated with 2 μg/mL recombinant 
ACE2 protein, then washed and blocked with 3% BSA in 1X PBS. While 
assay plates blocked, purified antibodies were diluted as stated above, 
only in 1% BSA with 0.05% Tween-20. In a separate dilution plate Spike-2P 



























the EC50 at which spike binds to ACE2 protein. The mixture was allowed 
to incubate at room temperature for 1 hour. Blocked assay plates were 
then washed and the antibody-spike mixture was added to the assay 
plates for a period of 1 hour at room temperature. Plates were washed 
and a polyclonal rabbit serum against the same spike protein (nCoV-1 
nCoV-2P.293F) was added for 1 hour, washed and detected with goat 
anti rabbit-HRP (Abcam cat# ab97080) followed by TMB substrate. 
The extent to which antibodies were able to block the binding spike 
protein to ACE2 was determined by comparing the OD of antibody 
samples at 450 nm to the OD of samples containing spike protein only 
with no antibody. The following formula was used to calculate percent 
blocking: blocking% = (100 - (OD sample/OD of spike only)*100).
Plasma and mucosal IgG blocking of RBD monoclonal antibody 
binding
Blocking assays for DH1041 and DH1047 were performed as stated 
above for ACE2, except plates were coated with either DH1041 or 
DH1047 instead of ACE2.
Plasma and mucosal IgG ELISA binding assays
For ELISA binding assays of Coronavirus Spike antibodies, the anti-
gen panel included SARS-CoV-2 Spike S1+S2 ectodomain (ECD) (SINO, 
Catalog # 40589-V08B1), SARS-CoV-2 Spike-2P54, SARS-CoV-2 Spike S2 
ECD (SINO, Catalog # 40590-V08B), SARS-CoV-2 Spike RBD from insect 
cell sf9 (SINO, Catalog # 40592-V08B), SARS-CoV-2 Spike RBD from 
mammalian cell 293 (SINO, Catalog # 40592- V08H), SARS-CoV-2 Spike 
NTD-Biotin, SARS-CoV Spike Protein DeltaTM (BEI, Catalog # NR-722), 
SARS-CoV WH20 Spike RBD (SINO, Catalog # 40150-V08B2), SARS-CoV 
WH20 Spike S1 (SINO, Catalog #40150-V08B1), SARS-CoV-1 RBD, 
MERS-CoV Spike S1+S2 (SINO, Catalog # 40069-V08B), MERS-CoV Spike 
S1 (SINO, Catalog #40069-V08B1), MERS-CoV Spike S2 (SINO, Catalog 
#40070-V08B), MERS-CoV Spike RBD (SINO, Catalog #40071-V08B1), 
MERS-CoV Spike RBD.
For binding ELISA, 384-well ELISA plates were coated with 2 μg/mL 
of antigens in 0.1 M sodium bicarbonate overnight at 4 °C. Plates were 
washed with PBS + 0.05% Tween 20 and blocked with assay diluent (PBS 
containing 4% (w/v) whey protein, 15% Normal Goat Serum, 0.5% Tween-
20, and 0.05% Sodium Azide) at room temperature for 1 hour. Plasma or 
mucosal fluid were serially diluted three-fold in superblock starting at a 
1:30 dilution. Nasal was fluid started from neat and diluted 1:30, whereas 
BAL fluid was concentrated 10-fold. To concentrate BAL, individual 
BAL aliquots from the same animal and same time point were pooled 
in 3KDa MWCO ultrafiltration tubes (Sartorious #VS2091). Pooled 
BAL was concentrated by centrifugation at 3500 rpm for 30 minutes 
or until volume was reduced by a factor of 10. Pool was then aliquoted 
and frozen at -80 °C until its use in an assay. Purified mAb samples were 
diluted to 100 μg/mL and then serially diluted 3-fold in assay diluent. 
Samples were added to the antigen-coated plates, and incubated for 
1 h, followed by washes with PBS-0.1% Tween 20. HRP-conjugated goat 
anti-human IgG secondary Ab or mouse anti-rhesus IgG secondary anti-
body (SouthernBiotech, catalog #2040-05) was diluted to 1:10,000 and 
incubated at room temperature for 1 hour. These plates were washed 
four times and developed with tetramethylbenzidine substrate (Sure-
Blue Reserve- KPL). The reaction was stopped with 1 M HCl, and optical 
density at 450 nm (OD450) was determined.
Subgenomic RNA real time PCR quantification
The assay for SARS-CoV-2 quantitative Polymerase Chain Reaction 
(qPCR) detects total RNA using the WHO primer/probe set E_Sar-
beco (Charité/Berlin). A QIAsymphony SP (Qiagen, Hilden, Germany) 
automated sample preparation platform along with a virus/pathogen 
DSP midi kit and the complex800 protocol were used to extract viral 
RNA from 800 μL of pooled samples. A reverse primer specific to the 
envelope gene of SARS-CoV-2 (5’-ATA TTG CAG CAG TAC GCA CAC A-3’) 
was annealed to the extracted RNA and then reverse transcribed into 
cDNA using SuperScriptTM III Reverse Transcriptase (Thermo Fisher 
Scientific, Waltham, MA) along with RNAse Out (Thermo Fisher Sci-
entific, Waltham, MA). The resulting cDNA was treated with RNase H 
(Thermo Fisher Scientific, Waltham, MA) and then added to a custom 
4x TaqManTM Gene Expression Master Mix (Thermo Fisher Scientific, 
Waltham, MA) containing primers and a fluorescently labeled hydrolysis 
probe specific for the envelope gene of SARS-CoV-2 (forward primer 
5’-ACA GGT ACG TTA ATA GTT AAT AGC GT-3’, reverse primer 5’-ATA TTG 
CAG CAG TAC GCA CAC A-3’, probe 5’-6FAM/AC ACT AGC C/ZEN/A TCC 
TTA CTG CGC TTC G/IABkFQ-3’). The qPCR was carried out on a QuantS-
tudio 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA) 
using the following thermal cycler parameters: heat to 50 °C, hold for 
2 min, heat to 95 °C, hold for 10 min, then the following parameters are 
repeated for 50 cycles: heat to 95 °C, hold for 15 seconds, cool to 60 °C 
and hold for 1 minute. SARS-CoV-2 RNA copies per reaction were inter-
polated using quantification cycle data and a serial dilution of a highly 
characterized custom DNA plasmid containing the SARS-CoV-2 envelope 
gene sequence. Mean RNA copies per milliliter were then calculated 
by applying the assay dilution factor (DF=11.7). The limit of detection 
(LOD) for this assay is approximately 62 RNA copies per mL of sample.
Recombinant IgG production
Expi293-F cells were diluted to 2.5E6 cells/mL on the day of transfection. 
Cells were co-transfected with Expifectamine and heavy and light chain 
expression plasmids. Enhancers were added 16h after transfection. On 
day 5, the cell culture was cleared of cells by centrifugation, filtered, 
and incubated with protein A beads overnight. The next day the protein 
A resin was washed with Tris buffered saline and then added to a 25 mL 
column. The resin was washed again and then glacial acetic acid was 
used to elute antibody off of the protein A resin. The pH of the solution 
was neutralized with 1M Tris pH8. The antibody was buffer exchanged 
into 25 mM sodium citrate pH6 supplemented with 150 mM NaCl, 
0.2 μm filtered, and frozen at -80 °C.
Negative stain electron microscopy
The RBD nanoparticle protein at ~1-5 mg/ml concentration that had 
been flash frozen and stored at -80 °C was thawed in an aluminum block 
at 37 °C for 5 minutes; then 1-4 μL of RBD nanoparticle was diluted 
to a final concentration of 0.1 mg/ml into room-temperature buffer 
containing 150 mM NaCl, 20 mM HEPES pH 7.4, 5% glycerol, and 7.5 mM 
glutaraldehyde. After 5 minutes cross-linking, excess glutaraldehyde 
was quenched by adding sufficient 1 M Tris pH 7.4 stock to give a final 
concentration of 75 mM Tris and incubated for 5 minutes. For negative 
stain, carbon-coated grids (EMS, CF300-cu-UL) were glow-discharged 
for 20s at 15 mA, after which a 5-μl drop of quenched sample was incu-
bated on the grid for 10-15 s, blotted, and then stained with 2% uranyl 
formate. After air drying grids were imaged with a Philips EM420 elec-
tron microscope operated at 120 kV, at 82,000× magnification and 
images captured with a 2k x 2k CCD camera at a pixel size of 4.02 Å.
Processing of negative stain images
The RELION 3.0 program was used for all negative stain image process-
ing. Images were imported, CTF-corrected with CTFFIND, and particles 
were picked using a spike template from previous 2D class averages of 
spike alone. Extracted particle stacks were subjected to 2-3 rounds of 
2D class averaging and selection to discard junk particles and back-
ground picks. Cleaned particle stacks were then subjected to 3D clas-
sification using a starting model created from a bare spike model, PDB 
6vsb, low-pass filtered to 30 Å. Classes that showed clearly-defined Fabs 
were selected for final refinements followed by automatic filtering and 
B-factor sharpening with the default Relion post-processing parameters.
Betacoronavirus sequence analysis
Heatmaps of amino acid sequence similarity were computed for a repre-



























in R. Briefly, 1408 betacoronavirus sequences were retrieved from NCBI 
Genbank, aligned to the Wuhan-1 spike protein sequence, and trimmed 
to the aligned region. The 1408 spike sequences were then clustered 
using USEARCH64 with a sequence identity threshold of 0.90 resulting 
in 52 clusters. We sampled one sequence from each cluster to generate 
a representative set of sequences. Five betacoronavirus sequences 
of interest not originally included in the clustered set were added: 
SARS-CoV-2, GXP4L, batCoV-RaTG13, batCoV-SHC014, batCoV-WIV-1. 
This resulted in a set of 57 representative spike sequences. Pairs of 
spike amino acid sequences were aligned using a global alignment and 
the BLOSUM62 scoring matrix. For RBD and NTD domain alignments, 
spike sequences were aligned to the Wuhan 1 spike protein RBD region 
(residues 330-521) and NTD region (residues 27-292), respectively, 
and trimmed to the aligned region. Phylogenetic tree construction of 
RBD sequences was performed with Geneious Prime 2020.1.2 using 
the Neighbor Joining method and default parameters. To map group 
2b betaCoV sequence conservation onto the RBD structure, group 2b 
spike sequences were retrieved from Genbank and clustered using 
USEARCH64 with a sequence identity threshold of 0.99 resulting in 
39 clusters. For clusters of size >5, 5 spike sequences were randomly 
downsampled from each cluster. The resulting set of 73 sequences was 
aligned using MAFFT65. Conservation scores for each position in the 
multiple sequence alignment were calculated using the trident scoring 
method66 and computed using the MstatX program (https://github.
com/gcollet/MstatX). The conservation scores were then mapped to 
the RBD domain coordinates (PDB: 7LD1) and images rendered with 
PyMol version 2.3.5.
Histopathology
Lung specimen from macaques were fixed in 10% neutral-buffered 
formalin, processed, and blocked in paraffin for histology analyses. 
All tissues were sectioned at 5 μm and stained with hematoxylin-eosin 
(H&E) for to assess histopathology. Stained sections were evaluated 
by a board-certified veterinary pathologist in a blinded manner. 
Sections were examined under light microscopy using an Olympus 
BX51 microscope and photographs were taken using an Olympus 
DP73 camera.
Immunohistochemistry (IHC)
Staining for SARS-CoV-2 nucleocapsid antigen was performed by the 
Bond RX automated system with the Polymer Define Detection System 
(Leica) following the manufacturer’s protocol. Tissue sections were 
dewaxed with Bond Dewaxing Solution (Leica) at 72 °C for 30 min, then 
subsequently rehydrated with graded alcohol washes and 1x Immuno 
Wash (StatLab). Heat-induced epitope retrieval (HIER) was performed 
using Epitope Retrieval Solution 1 (Leica) and by heating the tissue 
section to 100 °C for 20 min. A peroxide block (Leica) was applied for 
5 min to quench endogenous peroxidase activity prior to applying the 
SARS-CoV-2 nucleocapsid antibody (1:2000, GeneTex, GTX135357). 
Antibodies were diluted in Background Reducing Antibody Diluent 
(Agilent). The tissue was subsequently incubated with an anti-rabbit 
HRP polymer (Leica) and colorized with 3,3’-Diaminobenzidine (DAB) 
chromogen for 10 min. Slides were counterstained with hematoxylin.
Reagent authentication
Cell lines were received with a certificate of authentication certify-
ing their identity. Cell identity was also confirmed by visualizing cell 
morphology and using flow cytometry to detect cell surface proteins. 
Cells were confirmed to be free of mycoplasma with monthly testing.
Statistics analysis
Data were plotted using Prism GraphPad 9.0. Wilcoxon rank sum 
exact test was performed to compare differences between groups 
with p-value < 0.05 considered significant using SAS 9.4 (SAS Insti-
tute, Cary, NC). No adjustments were made to the p-values for multiple 
comparisons. IC50 and IC80 values were calculated using R statisti-
cal software (version 4.0.0; R Foundation for Statistical Computing, 
Vienna, Austria). The R package ‘nplr’ was used to fit 4-Parameter 
Logistic (4-PL) regression curves to the average values from duplicate 
experiments, and these fits were used to estimate the concentrations 
corresponding to 50% and 80% neutralization.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
The authors declare that the data supporting the findings of this study 
are available within the main and supplemental figures. All data is avail-
able in the Source Data File. Source data are provided with this paper.
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Extended Data Fig. 1 | Molecular and structural characterization of the 
SARS-CoV-2 RBD sortase A conjugated nanoparticle. a Size exclusion 
chromatography of RBD and ferritin sortase conjugation. The first peak shows 
conjugated protein. The second peak contains unconjugated RBD. b Analytical 
size exclusion trace shows a homogenous nanoparticle preparation. c Negative 
stain electron microscopy image of RBD-scNPs on a carbon grid. Inset shows a 
zoomed image of RBD-scNP. The zoomed image shows RBD molecules arrayed 
around the outside of the ferritin nanoparticle. A representative image from 
the 31 images taken of the micrograph to visualize 13,827 total particles is 
shown. d Chemical structure of toll-like receptor 7 and 8 agonist 3M-052. Alum 
formulation of 3M-052 was used to adjuvant RBD-scNP immunization. e RBD-
scNP immunization regimen used for vaccination of cynomolgus macaques 
(N=5). Blue arrows indicate timepoints for intramuscular immunizations with 
RBD-scNP (100 μg) adjuvanted with 3M-052 (5 μg 3M-052 plus 500 μg Alum). 
Bronchoalveolar lavage (BAL, orange arrows) and nasal swab (green arrows) 
fluids were collected 7 days before, 2 days after, and 4 days after intratracheal/
intranasal SARS-CoV-2 challenge (black arrow). f Transmembrane, diproline-
stabilized spike (S-2P) mRNA-LNP prime, RBD-scNP boost vaccination of 
cynomolgus macaques (N=5). Maroon arrows indicate timepoints for S-2P 
mRNA-LNP immunization (50 μg mRNA dose). Blue arrows are the same as  
in a. Macaques were challenged 9 weeks after RBD-scNP boost (week 17 of the 
study). BAL and nasal swab fluids were collected as in a. Macaques were 
challenged at week 17 (black arrow). g Monomeric RBD mRNA-LNP 
immunization of rhesus macaques (N=8). Tan arrows indicate timepoints for 
RBD mRNA-LNP immunization (50 μg mRNA dose). Blood was collected 



























Extended Data Fig. 2 | Blood chemical analysis and blood cell counts in 
RBD-scNP and S-2P mRNA-LNP-vaccinated macaques. Each graph shows 
values for individual macaques before vaccination and 4 weeks after the 
RBD-scNP (week 8) or 6 weeks after the second S-2P mRNA-LNP immunization 
(week 10). RBD-scNP-immunized macaques are shown as blue symbols, and 
S-2P mRNA-LNP immunized macaques are shown as red symbols. The reference 
range for each value is shown as gray shaded area for female macaques and cyan 
shaded area for male macaques. Creatine kinase does not have a reference 




























Extended Data Fig. 3 | ACE-2, RBD neutralizing antibody, and post-vaccination 
macaque plasma IgG binding to SARS-CoV-2 Spike variants. a,b Plasma IgG 
from macaques prior to immunization or after being immunized once with 
RBD-scNP adjuvanted with 3M-052-Alum (blue), RBD-scNP only (gray), or 
3M-052-Alum only (white). Binding titers as log AUC were determined a before or 
b two weeks after a single immunization. Horizontal bars are the group mean. 
ECD, ectodomain; S-2P, diproline-stabilized spike. c ACE2 receptor and 
cross-nAbDH1047 ELISA binding to SARS-CoV-2 Spike ectodomain (ECD) based on 
a Danish mink (H69/V70deI/Y453F/D614G/I692V), B.1.351-like (K417N/E484K/
N501Y/D614G), and B.1.1.7 (H69/V70del/Y144del/N501Y/A570D/D614G/P681H/
T716I/S982A/D1118H) strains. Titers are shown as area under the log-transformed 
curve (log AUC). d RBD-scNP and S-2P mRNA-LNP-immunized macaque serum IgG 
ELISA binding to SARS-CoV-2 Spike variants shown in c. Serum was tested after 
two immunizations. Horizontal bars are the group mean. e ACE2 receptor (gray), 
cross-nAbDH1047 (navy), and ACE2 binding site-targeting neutralizing antibody 
DH1041 (green) ELISA binding to SARS-CoV-2 Spike RBD monomers. RBD variants 
contain a subset of mutations found in circulating B.1.351 and P.1 virus strains. 
Titers are shown as area under the log-transformed curve (log AUC). f RBD-scNP 
and S-2P mRNA-LNP-immunized macaque serum IgG ELISA binding to 
SARS-CoV-2 Spike RBD variants shown in e. Serum was tested after two 





























Extended Data Fig. 4 | Cross-neutralizing antibodies are elicited by 
recombinant protein RBD-scNP and mRNA-LNP immunization. a Each row 
shows neutralization titer for an individual macaque immunized with one of 
the three immunogens. A reciprocal serum dilution titer of 87,480 is the upper 
limit of detection and 20 is the lower limit of detection for this assay. Titers are 
derived from a nonlinear regression curve fit to the average of duplicate 
measurements. b,c Serum neutralization titers elicited by two S-2P mRNA-LNP 
immunizations were boosted by a subsequent RBD-scNP immunization. Serum 
neutralization of a SARS-CoV-2 D614G and b SARS-CoV-2 B.1.1.7 pseudovirus 
infection of ACE2-expressing 293 cells. Neutralization titers are ID50 as 
reciprocal serum dilution for serum collected two weeks after the second 
(week 6) and third immunization (week 10). Each symbol connected by a line 
represents the titer for an individual macaque before and after RBD-scNP 





























Extended Data Fig. 5 | Cross-reactive plasma antibody responses elicited 
by RBD-NP immunization in macaques. a Plasma IgG from macaques 
immunized twice with RBD-scNP binds to Spike from human, bat, and pangolin 
SARS-related coronavirus Spike (S) in ELISA, but not endemic human 
coronaviruses or MERS-CoV. ECD, ectodomain. b Determination of DH1047 
antigen binding fragment (Fab) binding kinetics to RBD monomer by surface 
plasmon resonance. Each curve shows a different concentration of DH1047 
Fab. Binding kinetics are shown to the right from a 1:1 model fit. c Time course 
of vaccinated macaque plasma IgG binding to human, bat, and pangolin 
coronavirus S protein by ELISA. Each curve indicates the binding titer for an 
individual macaque. Arrows indicate immunization time points.  
d Unimmunized macaque plasma antibody blocking of SARS-CoV-2 S-2P (left) 
and batCoV-SHC014 (middle) binding to ACE2-Fc, RBD neutralizing antibody 
DH1041, and RBD cross-nAbDH1047. (Right) Blocking activity in the serum of 
humans immunized with Pfizer S-2P mRNA-LNP vaccine (N=4). Each symbol 



























Extended Data Fig. 6 | Multiple Sequence Alignment of Spike Protein from a 
Representative Set of Group 2b Betacoronaviruses. SARS-CoV-2 Wuhan-1 
spike protein numbering is shown. NTD=N-terminal domain; RBD=receptor 
binding domain; S1/S2=SARS2 furin cleavage site; FP=fusion peptide; 
HR1=heptad repeat 1; HR2=heptad repeat 2; CH=central helix; CD=connecting 
domain; TM=transmembrane domain. ACE2 contact positions in SARS2 




























Extended Data Fig. 7 | Sequence conservation among SARS-related 
betaCoV, MERS-CoV, and endemic human CoVs. a,b Sequence similarity of a 
RBD and b spike protein for representative betacoronaviruses. Heatmaps 
displaying pairwise amino acid sequence similarity for 57 representative 
betacoronaviruses. Dark blue shading indicates high sequence similarity. c List 
of viruses used for alignments in a and Fig. 3f. d Phylogenetic tree of 
representative betacoronavirus RBD sequences. Group 2b betaCoVs of interest 



























Extended Data Fig. 8 | Histology and immunohistochemistry of lung tissue 
collected seven days after SARS-CoV-2 WA-1 intratracheal and intranasal 
challenge. a-c Macaques were immunized a thrice with RBD-scNP, b twice with 
S-2P mRNA-LNP and once with RBD-scNP, or c unimmunized. Each column 
shows results from an individual macaque. The macaque identification 
number is shown above each column. Hematoxylin and eosin stain of lung 
sections are shown on the top row, with nucleocapsid immunohistochemistry 
shown on the bottom row for each macaque. Red arrows indicate site of antigen 
positivity. All images are shown at 10X magnification with 100 micron scale 




























Extended Data Fig. 9 | Mucosal SARS-CoV-2 IgG responses in bronchoalveolar 
lavage (BAL) and nasal wash fluids before and after SARS-CoV-2 challenge.  
a ELISA binding titers for SARS-CoV-2-specific IgG in 10X BAL fluid from 
macaques immunized with (blue symbols, left column) RBD-scNP three times or 
S-2P mRNA-LNP twice and RBD-scNP once (red symbols, left column). Day -7 BAL 
fluid was collected at week 10 or 16 for the RBD-scNP alone group or the S-2P 
mRNA-LNP/RBD-scNP group respectively. Group mean±s.e.m. are shown (N=5). 
b-d 10X BAL fluid blocking of ACE2, RBD neutralizing antibody DH1041, and 
cross-nAbDH1047 binding to SARS-CoV-2 D614G stabilized spike ectodomain.  
A black horizontal bar indicates the group mean blocking percentage. Blocking 
above 20% (above the dashed line) is considered positive. e Neat nasal wash fluid 
from RBD-scNP-immunized or S-2P mRNA-LNP/RBD-scNP-immunized macaques. 
Day -7 nasal wash fluid was collected at week 16 and 2 and 4 days post challenge 
for the S-2P mRNA-LNP/RBD-scNP group. Nasal wash fluid was unavailable for the 
RBD-scNP before challenge, but was collected 2 and 4 days after the week 11 



























Extended Data Table 1 | Scoring of Hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) of macaque lung 
tissue collected seven days after challenge
a H&E (inflammation): - = minimal – absent, +/- = minimal – mild, + = mild to moderate, ++ = moderate-severe, +++ = severe. b IHC (SARS-CoV-2 nucleocapsid Ag positive foci): - = no SARS-CoV-2 
Ag detected, +/- = rare- occasional, + = occasional-multiple), ++ = multiple- numerous (foci often larger), +++ = numerous.
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